PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
BTEK.L vs. ARKG
Performance
Return for Risk
Drawdowns
Volatility
Dividends

BTEK.L vs. ARKG

Last updated Jun 5, 2026

BTEK.L (iShares Nasdaq US Biotechnology UCITS ETF) and ARKG (ARK Genomic Revolution Multi-Sector ETF) are both Health & Biotech Equities funds. BTEK.L is passively managed, while ARKG is actively managed. Over the past 5 years, BTEK.L returned 5.85%/yr vs -13.66%/yr for ARKG. At a 0.49 correlation, their price movements are largely independent. BTEK.L charges 0.35%/yr vs 0.75%/yr for ARKG.

Performance

BTEK.L vs. ARKG - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) and ARK Genomic Revolution Multi-Sector ETF (ARKG). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Different Trading Currencies

BTEK.L is traded in GBP, while ARKG is traded in USD. To make them comparable, the ARKG values have been converted to GBP using the latest available exchange rates.

Returns By Period

In the year-to-date period, BTEK.L achieves a 4.86% return, which is significantly lower than ARKG's 25.71% return.

BTEK.L

1D
3.56%
1M
2.25%
YTD
4.86%
6M
2.70%
1Y
43.15%
3Y*
10.19%
5Y*
5.85%
10Y*
—

ARKG

1D
6.93%
1M
22.91%
YTD
25.71%
6M
12.91%
1Y
61.97%
3Y*
0.10%
5Y*
-13.66%
10Y*
8.54%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BTEK.L vs. ARKG - Yearly Performance Comparison

2026 (YTD)202520242023202220212020201920182017
BTEK.L
iShares Nasdaq US Biotechnology UCITS ETF		4.86%23.81%-0.32%0.33%-1.55%0.90%23.11%21.63%-6.34%-3.31%
ARKG
ARK Genomic Revolution Multi-Sector ETF		25.71%14.28%-26.98%10.41%-48.42%-33.29%172.17%38.52%4.59%-6.62%

Correlation

The correlation between BTEK.L and ARKG is 0.43, which is low. Their price movements are largely independent, making them effective diversification partners.

Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.43

Correlation (3Y)
Calculated over the trailing 3-year period

0.47

Correlation (5Y)
Calculated over the trailing 5-year period

0.46

Correlation (All Time)
Calculated using the full available price history since Oct 25, 2017

0.49

BTEK.L vs. ARKG - Sectors Allocation Comparison

Sectors
BTEK.L
ARKG

Healthcare

100.0%
99.2%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Financial Services

-

0.5%

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

BTEK.L
100.0%
ARKG
99.2%

Basic Materials

BTEK.L

-

ARKG

-

Communication Services

BTEK.L

-

ARKG

-

Consumer Cyclical

BTEK.L

-

ARKG

-

Consumer Defensive

BTEK.L

-

ARKG

-

Energy

BTEK.L

-

ARKG

-

Financial Services

BTEK.L

-

ARKG
0.5%

Industrials

BTEK.L

-

ARKG

-

Real Estate

BTEK.L

-

ARKG

-

Technology

BTEK.L

-

ARKG

-

Utilities

BTEK.L

-

ARKG

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

iShares Nasdaq US Biotechnology UCITS ETF

ARK Genomic Revolution Multi-Sector ETF

Often compared with BTEK.L:
BTEK.L vs. SBIO.LBTEK.L vs. BRK-BBTEK.L vs. IBBQBTEK.L vs. XLKBTEK.L vs. QQQBTEK.L vs. GOOGBTEK.L vs. BTC-USD
Often compared with ARKG:
ARKG vs. ARKKARKG vs. XBIARKG vs. IBBARKG vs. GNOMARKG vs. IDNAARKG vs. ARKQARKG vs. ARKW

Return for Risk

BTEK.L vs. ARKG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
BTEK.L
BTEK.L Risk / Return Rank: 7676
Overall Rank
BTEK.L Sharpe Ratio Rank: 7070
Sharpe Ratio Rank
BTEK.L Sortino Ratio Rank: 7070
Sortino Ratio Rank
BTEK.L Omega Ratio Rank: 6363
Omega Ratio Rank
BTEK.L Calmar Ratio Rank: 9292
Calmar Ratio Rank
BTEK.L Martin Ratio Rank: 8585
Martin Ratio Rank
ARKG
ARKG Risk / Return Rank: 4141
Overall Rank
ARKG Sharpe Ratio Rank: 4242
Sharpe Ratio Rank
ARKG Sortino Ratio Rank: 4444
Sortino Ratio Rank
ARKG Omega Ratio Rank: 3838
Omega Ratio Rank
ARKG Calmar Ratio Rank: 4646
Calmar Ratio Rank
ARKG Martin Ratio Rank: 3636
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BTEK.L vs. ARKG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

BTEK.LARKGDifference
Sharpe ratioReturn per unit of total volatility
2.24
1.55

+0.70

Sortino ratioReturn per unit of downside risk
3.13
2.26

+0.87

Omega ratioGain probability vs. loss probability

1.38

1.26

+0.12

Calmar ratioReturn relative to maximum drawdown

6.23

2.42

+3.81

Martin ratioReturn relative to average drawdown

17.55

5.62

+11.94

Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BTEK.L vs. ARKG - Sharpe Ratio Comparison

The current BTEK.L Sharpe Ratio is 2.24, which is higher than the ARKG Sharpe Ratio of 1.55. The chart below compares the historical Sharpe Ratios of BTEK.L and ARKG, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Loading charts...

Sharpe Ratios by Period

BTEK.LARKGDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.24

1.55

+0.70

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.29

-0.31

+0.60

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

—

0.21

—

Sharpe Ratio (All Time)

Calculated using the full available price history

0.31

0.19

+0.12

Drawdowns

BTEK.L vs. ARKG - Drawdown Comparison

The maximum BTEK.L drawdown since its inception was -30.86%, smaller than the maximum ARKG drawdown of -82.46%. Use the drawdown chart below to compare losses from any high point for BTEK.L and ARKG.

Loading charts...

Drawdown Indicators

BTEK.LARKGDifference

Max Drawdown

Largest peak-to-trough decline

-30.86%

-82.46%

+51.60%

Max Drawdown (1Y)

Largest decline over 1 year

-6.89%

-25.76%

+18.87%

Max Drawdown (3Y)

Largest decline over 3 years

-26.34%

-51.48%

+25.14%

Max Drawdown (5Y)

Largest decline over 5 years

-30.86%

-78.58%

+47.72%

Max Drawdown (10Y)

Largest decline over 10 years

—

-82.46%

—

Current Drawdown

Current decline from peak

-1.86%

-66.98%

+65.12%

Average Drawdown

Average peak-to-trough decline

-10.04%

-34.46%

+24.42%

Ulcer Index

Depth and duration of drawdowns from previous peaks

2.45%

11.06%

-8.61%

Volatility

BTEK.L vs. ARKG - Volatility Comparison

The current volatility for iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) is 6.91%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 12.28%. This indicates that BTEK.L experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading charts...

Volatility by Period

BTEK.LARKGDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.91%

12.28%

-5.37%

Volatility (6M)

Calculated over the trailing 6-month period

14.67%

28.19%

-13.52%

Volatility (1Y)

Calculated over the trailing 1-year period

19.14%

40.34%

-21.20%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

20.08%

43.88%

-23.80%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

21.71%

40.33%

-18.62%

BTEK.L vs. ARKG - Expense Ratio Comparison

BTEK.L has a 0.35% expense ratio, which is lower than ARKG's 0.75% expense ratio.

Dividends

BTEK.L vs. ARKG - Dividend Comparison

Neither BTEK.L nor ARKG has paid dividends to shareholders.

PositionTTM202520242023202220212020201920182017
ARKG
ARK Genomic Revolution Multi-Sector ETF		0.00%0.00%0.00%0.00%0.00%0.62%0.85%3.14%0.82%1.34%
BTEK.L
iShares Nasdaq US Biotechnology UCITS ETF		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions

BTEK.L and ARKG have a correlation of 0.43, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

On fees, BTEK.L is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.

BTEK.L is cheaper with a 0.35% expense ratio, compared with 0.75% for ARKG.

They also come from different issuers: iShares and ARK. Their fees differ too: 0.35% for BTEK.L and 0.75% for ARKG.

Portfolio Optimizer

Find the right allocation for BTEK.L and ARKG

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer